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and Recurrent Stroke*
Alex Abou-Chebl, MDI schemic stroke is a complex condition with mul-tiple possible causes, but up to 30% to 40% ofpatients have no identiﬁable source despite a
“thorough” evaluation; that is, the strokes are cryp-
togenic. Paradoxical embolism via a patent foramen
ovale (PFO) is the cause of some of those cryptogenic
strokes, which has led to a great interest in percuta-
neous closure of PFOs. However, 3 randomized trials
have not shown superiority of PFO closure over
medical therapy, casting a great deal of doubt over
the utility of percutaneous PFO closure (1–3). The
concept of PFO closure is sound, so the question is:
why were the trials unable to show beneﬁt? The
answers to that question are simple and complex
at the same time, and are not entirely known. The
complexity of stroke is poorly understood by many,
including physicians. This often leads to a desire
to simplify the evaluation and treatment, creating
generalizations such as “a PFO is present, thereforeSEE PAGE 913it is the cause of the stroke.” These cookbook
approaches cause detrimental clinical and scientiﬁc
effects. In other words, patient selection is the most
essential aspect of any stroke trial, and this is where
the PFO closure trials may have failed.
To address this concern, in this issue of JACC:
Cardiovascular Interventions, Elmariah et al. (4) con-
ducted a post-hoc analysis of the CLOSURE I (Evalu-
ation of the STARFlex Septal Closure System
in Patients With a Stroke and/or Transient Ischemic
Attack due to Presumed Paradoxical Embolism
Through a Patent Foramen Ovale) trial to identify
risk factors for recurrent stroke. They performed an
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risk factors (hypertension, diabetes mellitus, and so
on), as well as atrial ﬁbrillation/ﬂutter that had
developed after randomization. Most importantly,
they also categorized patients with the Risk of Par-
adoxical Embolism (RoPE) score, which was not
devised until after the CLOSURE trial had ended (5).
This score was shown in a retrospective study of
3,674 patients to be able to: 1) predict the likelihood
of PFO in cryptogenic stroke patients; and 2) deﬁne
the PFO-attributable risk (6). The RoPE score (range
0 to 10) gives patients points for factors that favor
paradoxical embolism and removes points for factors
that favor other etiologies; hence, a low score (e.g.,
0) is associated with a low (approaching 0%) risk of
stroke attributable to the PFO, whereas a high score
(e.g., 10) has a >80% PFO-attributable risk of stroke.
In this analysis, the investigators found that pa-
tients with recurrent neurological events (in the
CLOSURE I study, these were deﬁned as stroke or
“hard” transient ischemic attack [TIA]) had a higher
prevalence of traditional vascular (i.e., atheroscle-
rosis) risk factors, especially hypertension, diabetes
mellitus, ischemic heart disease, and higher bodymass
index. On multivariable analyses, they found that
diabetes, index event as TIA, and post-closure devel-
opment of atrial ﬁbrillation predicted recurrent
ischemic events.When they compared the RoPE scores
and the risk of recurrent events, they found that
“paradoxically,” the risk of recurrent events (14.5%
risk) was highest in those with the lowest RoPE score
(#5). The investigators correctly concluded that a
“substantial proportion of recurrent events within the
CLOSURE I trial were not due to paradoxical emboli-
zation.” Atherosclerosis was a likely cause of many of
the recurrent events. Reassuringly, they also found
that a RoPE score >5 was found in 85.6% of patients in
the CLOSURE I trial, indicating that the trial had
enrolled mostly appropriate patients, but their risk of
recurrent events was only 4.2%. Therefore, the 14% of
patients with atherosclerosis risk factors included in
the trial muddied the waters sufﬁciently to decrease
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922the power of the trial of ﬁnding superiority of PFO
closure. This was exacerbated by the fact that there
was not a standardized medical treatment regimen for
the medical arm. Those patients could be treated with
warfarin or aspirin at the discretion of the treating
physician, and there was no stipulation on risk factor
control. The endovascular arm, however, was treated
with dual antiplatelet therapy for 6 months, which has
recently been shown in a Chinese population to be
superior to a single agent for stroke prevention (7).
The other important ﬁnding by Elmariah et al. (4)
was that an index event of TIA was a predictor of
recurrent neurological events, mostly recurrent TIA,
with a hazard ratio of 4.66 (p < 0.0001). This high-
lights a major limitation of the CLOSURE I trial and an
important point for other stroke prevention trials: the
index TIA events may not have been ischemic at all.
Mimics of cerebral ischemia such as migraine (which
has a high prevalence in those with PFO and stroke),
epilepsy, or psychiatric conditions, to name a few,
may have been the real causes. Not only are these
patients important to exclude from future trials, but
they likely represent a large proportion of patients
who are referred for PFO closure in the real world.
The authors correctly concluded that future trials, if
any, should only include patients with stroke or TIA,
with imaging conﬁrmation performed as in the other
2 PFO trials (2,3).
The limitations of this analysis are clearly
enumerated by the authors, but are primarily due to
issues with the dataset such as a low number of
neurological events as well as enrollment bias in the
CLOSURE I trial because of the ready availability of
PFO closure devices on the market during enrollment
and the 10 years it took to enroll the 909 patients.
Also, as the authors note, causation is implied, but
cannot be proven, by these data.Still, taken together, the ﬁndings of this post-hoc
analysis of the CLOSURE I trial represent a very
important addition to the knowledge base. They rein-
force the importance of proper patient selection for
clinical trials. This aspect of clinical trial design is
often compromised, not maliciously, but by external
pressures to complete trials as quickly as possible.
Randomized trials are incredibly expensive to con-
duct, and overly strict inclusion/exclusion criteria
slow recruitment and prolong enrollment. In fact,
the sponsor andmanufacturer of the device used in the
CLOSURE I trial, NMT Medical Inc., was essentially
bankrupted by the 10-year trial. Relatively lax entry
criteria, on the other hand, create heterogeneity and
often lead to negative trials; this is a very real
phenomenon in stroke trials, with recent trials of
intracranial stenting and endovascular acute stroke
therapy failing to prove efﬁcacy, at least in part
because of less than perfect patient selection (8).
These data also reinforce the importance of thorough
evaluation of all TIA and stroke patients, especially
the young. A carotid duplex ultrasound and an echo-
cardiogram, commonly the only evaluations a patient
receives, are not sufﬁcient. The entirety of the relevant
vasculature from the heart to the small branches of the
brain should be evaluated; prolonged monitoring for
atrial ﬁbrillation and tests for hypercoagulability
should also be considered before a diagnosis of para-
doxical embolism is contemplated (9). Last, these data
should be used by clinicians in helping to decide which
(rare) patient may be a candidate for PFO closure.
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